Hua Yuan Gao

20100130413, May 27, 2010

Oct 19, 2007

12/311962

Henry C. Marsh - Reading MA, US
Lawrence Thomas - Easton MA, US
Hua Gao - Farmington Hills MI, US
Xiaoxi Qiao - Farmington Hills MI, US

A61K 38/17
A61P 27/02

514 12

A method is disclosed for treating diseases or disorders of the eye involving undesired neovascularization by administration of a complement inhibitory protein such as soluble complement receptor type I (sCR1). The present invention relates to the direct treatment of macular degeneration, particularly age-related macular degeneration (AMD), by administering a complement inhibitory protein intraocularly or systemically.

20200308145, Oct 1, 2020

Oct 18, 2018

16/754349

- Thousand Oaks CA, US
Nagasree CHAKKA - Lexington MA, US
Hua GAO - Canton MA, US
Angel GUZMAN-PEREZ - Belmont MA, US
Daniel B. HORNE - Natick MA, US
Zihao HUA - Andover MA, US
Madeleine KIEFFER - Burlingame CA, US
Daniel C. H. Lin - Redwood City CA, US
Benjamin Charles MILGRAM - Cambridge MA, US
Jane PANTELEEV - Charlestown MA, US
Laurie SCHENKEL - Somerville MA, US
John STELLWAGEN - Beverly MA, US
Matthew WEISS - Boston MA, US
Ryan D. WHITE - Somerville MA, US
Wei ZHAO - Westford MA, US

Amgen Inc. - Thousand Oaks CA

C07D 401/14
C07D 471/10
C07D 471/04
C07D 498/04
C07D 401/04
C07D 403/04
C07D 413/14

The present invention relates to inhibitors of Transient Receptor Potential Channel 6 (TRPC6) protein activity. The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.

20200104589, Apr 2, 2020

Sep 13, 2019

16/570389

- Cupertino CA, US
Hua Gao - Sunnyvale CA, US
Hao Qin - Sunnyvale CA, US
Julia Benndorf - Sunnyvale CA, US

G06K 9/00
G06T 7/90
G06T 7/50
G06F 3/01
G06T 7/73

Some implementations of the disclosure involve, at a device having one or more processors, one or more image sensors, and an illumination source, detecting a first attribute of an eye based on pixel differences associated with different wavelengths of light in a first image of the eye. These implementations next determine a first location associated with the first attribute in a three dimensional (3D) coordinate system based on depth information from a depth sensor. Various implementations detect a second attribute of the eye based on a glint resulting from light of the illumination source reflecting off a cornea of the eye. These implementations next determine a second location associated with the second attribute in the 3D coordinate system based on the depth information from the depth sensor, and determine a gaze direction in the 3D coordinate system based on the first location and the second location.

20150057271, Feb 26, 2015

Feb 12, 2013

14/377478

- Thousand Oaks CA, US
Alessandro Boezio - Somerville MA, US
Howard Bregman - Melrose MA, US
Nagasree Chakka - Lexington MA, US
James R. Coats - Oak Harbor WA, US
Katrina Woodin Copeland - Sudbury MA, US
Erin F. Dimauro - Cambridge MA, US
Thomas Dineen - Somerville MA, US
Hua Gao - Canton MA, US
Daniel La - Brookline MA, US
Isaac E. Marx - Cambridge MA, US
Hanh Nho Nguyen - Arlington MA, US
Emily Anne Peterson - Cambridge MA, US
Matthew Weiss - Boston MA, US

C07D 417/14
C07D 471/04
C07D 413/14
C07D 417/12
C07D 413/12

5142305, 544105, 544353, 514249

The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.